Employees Retirement System of Texas Makes New Investment in Pfizer Inc. $PFE

Employees Retirement System of Texas purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 70,566 shares of the biopharmaceutical company’s stock, valued at approximately $1,711,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at about $27,000. Curio Wealth LLC grew its holdings in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $29,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in Pfizer during the 2nd quarter valued at approximately $33,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have weighed in on PFE shares. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.39.

Pfizer Stock Down 0.0%

PFE stock opened at $25.72 on Friday. The firm’s 50-day moving average is $24.97 and its two-hundred day moving average is $24.55. The company has a market capitalization of $146.21 billion, a price-to-earnings ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is currently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.